December 12, 2022
Hello Everyone,
An ABRF member asked us to post this question for your feedback:
As we know, the term 'core' can often be confused between the cores that offer chargeback rates and those used in grant terminologies, such as p30s or other grant-defined mechanisms.
What strategies do you use at your organization to help untangle/manage this message?
What nomenclature are you using to identify the differences between recharge and p30 cores or other grant-funded cores?
When do you need to intervene with a PI-born core (such as through a grant mechanism), charging other Investigators with a discussion on the need to document how their pricing is established? Is there an NIH reference on this subject?
Share your replies here and we'll compile the results.
Thank you.
------------------------------
Ken Schoppmann
ABRF
------------------------------